(-0.08%) 5 464.92 points
(-0.08%) 39 082 points
(0.17%) 17 748 points
(-0.71%) $80.26
(-4.32%) $2.64
(-0.84%) $2 311.20
(0.01%) $28.87
(2.32%) $1 009.30
(0.30%) $0.936
(0.73%) $10.68
(0.48%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs)...
Stats | |
---|---|
Today's Volume | 282 719 |
Average Volume | 745 490 |
Market Cap | 3.75B |
EPS | $-1.180 ( Q3 | 2023-09-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-57.86 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.455 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Viking Global Investors Lp | Sell | 1 743 556 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 498 510 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 494 687 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 864 509 | Common Stock |
2023-09-19 | Redmile Group, Llc | Sell | 498 510 | Series D Preferred Stock |
INSIDER POWER |
---|
-34.92 |
Last 21 transactions |
Buy: 7 015 868 | Sell: 14 005 880 |
Volume Correlation
RayzeBio, Inc. Common Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
RayzeBio, Inc. Common Correlation - Currency/Commodity
RayzeBio, Inc. Common Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.750 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
RayzeBio, Inc. Common
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators